IL178141A - Use of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridine-3-yl]-1,2-dioxoethyl]-piperazine in the manufacture of a medicament for use in conjunction with at least one other agent used for treatment of aids or hiv infection - Google Patents

Use of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridine-3-yl]-1,2-dioxoethyl]-piperazine in the manufacture of a medicament for use in conjunction with at least one other agent used for treatment of aids or hiv infection

Info

Publication number
IL178141A
IL178141A IL178141A IL17814106A IL178141A IL 178141 A IL178141 A IL 178141A IL 178141 A IL178141 A IL 178141A IL 17814106 A IL17814106 A IL 17814106A IL 178141 A IL178141 A IL 178141A
Authority
IL
Israel
Prior art keywords
dioxoethyl
pyrrolo
triazol
piperazine
benzoyl
Prior art date
Application number
IL178141A
Other languages
English (en)
Other versions
IL178141A0 (en
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL178141(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL178141A0 publication Critical patent/IL178141A0/en
Publication of IL178141A publication Critical patent/IL178141A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL178141A 2004-03-24 2006-09-17 Use of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridine-3-yl]-1,2-dioxoethyl]-piperazine in the manufacture of a medicament for use in conjunction with at least one other agent used for treatment of aids or hiv infection IL178141A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (2)

Publication Number Publication Date
IL178141A0 IL178141A0 (en) 2006-12-31
IL178141A true IL178141A (en) 2010-11-30

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178141A IL178141A (en) 2004-03-24 2006-09-17 Use of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridine-3-yl]-1,2-dioxoethyl]-piperazine in the manufacture of a medicament for use in conjunction with at least one other agent used for treatment of aids or hiv infection

Country Status (30)

Country Link
US (1) US7776863B2 (en:Method)
EP (1) EP1732604B1 (en:Method)
JP (1) JP4847441B2 (en:Method)
KR (1) KR101158140B1 (en:Method)
CN (1) CN1956720B (en:Method)
AR (1) AR048333A1 (en:Method)
AT (1) ATE474602T1 (en:Method)
AU (1) AU2005235116B2 (en:Method)
BR (1) BRPI0509140A (en:Method)
CA (1) CA2561146C (en:Method)
CY (1) CY1111613T1 (en:Method)
DE (1) DE602005022420D1 (en:Method)
DK (1) DK1732604T3 (en:Method)
ES (1) ES2347801T3 (en:Method)
GE (1) GEP20104925B (en:Method)
HR (1) HRP20100434T1 (en:Method)
IL (1) IL178141A (en:Method)
IN (1) IN2012DN06436A (en:Method)
MY (1) MY144318A (en:Method)
NO (1) NO337116B1 (en:Method)
NZ (1) NZ549778A (en:Method)
PE (1) PE20060148A1 (en:Method)
PL (1) PL1732604T3 (en:Method)
PT (1) PT1732604E (en:Method)
RU (1) RU2367439C2 (en:Method)
SI (1) SI1732604T1 (en:Method)
TW (1) TWI347184B (en:Method)
UA (1) UA88463C2 (en:Method)
WO (1) WO2005102392A2 (en:Method)
ZA (1) ZA200607959B (en:Method)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
DK1942108T3 (da) 2005-10-28 2013-12-09 Ono Pharmaceutical Co Forbindelse indeholdende basisk gruppe samt anvendelse deraf
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
ES2389478T3 (es) * 2008-06-25 2012-10-26 Bristol-Myers Squibb Company Derivados de dicetopiperidina como inhibidores de la fijación del VIH
JP5433690B2 (ja) * 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー 抗−ｈｉｖ薬としてのジケト縮合アゾロピペリジンおよびアゾロピペラジン
US20110295365A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
WO2012019003A1 (en) 2010-08-06 2012-02-09 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
EP2646439B1 (en) 2010-12-02 2016-05-25 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
WO2012106189A1 (en) 2011-01-31 2012-08-09 Bristol-Myers Squibb Company Methods of making hiv attachment inhibitor prodrug compound and intermediates
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
ES2616268T3 (es) 2011-08-29 2017-06-12 VIIV Healthcare UK (No.5) Limited Derivados condensados de diamina bicíclica como inhibidores de la unión de VIH
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
EP2895472B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
PT2978763T (pt) * 2013-03-27 2018-04-16 Viiv Healthcare Uk No 5 Ltd Derivados de 2-cetoamida como inibidores da ligação do vih
US11584797B2 (en) 2015-06-23 2023-02-21 Cytodyn Inc. Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions
US20250237642A1 (en) * 2022-03-08 2025-07-24 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045025A1 (en) * 1998-03-02 1999-09-10 The University Of North Carolina At Chapel Hill Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
PL370664A1 (en) * 2001-12-12 2005-05-30 Bristol-Myers Squibb Company Hiv integrase inhibitors
AU2002357379A1 (en) * 2001-12-21 2003-07-15 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Also Published As

Publication number Publication date
MY144318A (en) 2011-08-29
RU2006137555A (ru) 2008-04-27
JP2007530540A (ja) 2007-11-01
NO337116B1 (no) 2016-01-25
IL178141A0 (en) 2006-12-31
US20050215545A1 (en) 2005-09-29
RU2367439C2 (ru) 2009-09-20
TW200538117A (en) 2005-12-01
CY1111613T1 (el) 2015-10-07
ZA200607959B (en) 2008-06-25
WO2005102392A3 (en) 2006-07-20
ATE474602T1 (de) 2010-08-15
US7776863B2 (en) 2010-08-17
JP4847441B2 (ja) 2011-12-28
DK1732604T3 (da) 2010-11-15
KR101158140B1 (ko) 2012-06-19
BRPI0509140A (pt) 2007-09-04
TWI347184B (en) 2011-08-21
DE602005022420D1 (de) 2010-09-02
ES2347801T3 (es) 2010-11-04
HK1096540A1 (en) 2007-06-01
CA2561146A1 (en) 2005-11-03
SI1732604T1 (sl) 2010-10-29
PE20060148A1 (es) 2006-03-04
AR048333A1 (es) 2006-04-19
NZ549778A (en) 2010-09-30
IN2012DN06436A (en:Method) 2015-10-09
PL1732604T3 (pl) 2010-12-31
EP1732604B1 (en) 2010-07-21
GEP20104925B (en) 2010-03-25
WO2005102392A2 (en) 2005-11-03
NO20064547L (no) 2006-10-06
PT1732604E (pt) 2010-09-24
UA88463C2 (ru) 2009-10-26
AU2005235116A1 (en) 2005-11-03
HRP20100434T1 (hr) 2010-09-30
KR20070011322A (ko) 2007-01-24
CA2561146C (en) 2013-12-24
EP1732604A2 (en) 2006-12-20
CN1956720A (zh) 2007-05-02
CN1956720B (zh) 2010-12-15
AU2005235116B2 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
IL178141A (en) Use of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridine-3-yl]-1,2-dioxoethyl]-piperazine in the manufacture of a medicament for use in conjunction with at least one other agent used for treatment of aids or hiv infection
USD618353S1 (en) Controller for dental or metalworking handpiece
IL186881A (en) Pyrido derivatives [3,2– d] pyrimidine and their uses for the manufacture of drugs against hcv
AU2002367970A1 (en) Medical device for the treatment of a body vessel or another tubular structure in the body
IL203738A (en) Use of 1- (2-Isopropoxyethyl) -2-Theoxo-1, 2, 3, 5-Tetrahydro-Pyrolo [3, 2-d] Pyrimidine-4-On or its Acceptable Pharmaceutical Salt for the Preparation of a Multi-Systemic Degenerative Drug
IL169287A (en) Sterile ophthalmic formulation, an ocular insert for delivery of same and the use of the formulation
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
IL172614A (en) Use of dual nk1/nk3 antagonists in the preparation of medicaments for the treatment of schizophrenia
IL191769A0 (en) Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
EP1579833A4 (en) INDICATOR FOR A BODY FLUID ABSORBABLE ARTICLE
EP2005934A4 (en) COMMUNICATION ELEMENT, MEDICAL CONTAINER USING THE SAME, AND SET OF TOOLS FOR PREPARING INFUSION SOLUTION
USD553748S1 (en) X-ray apparatus for medical treatment
IL182624A0 (en) 2-amido-4 phenylthiazole derivatives, the preparation and the therapeutic use thereof
AU2003289010A1 (en) Needle body for medical use and liquid-introducing tool
AU2003294796A1 (en) Epothilone analogs for site specific delivery in the treatment of proliferative diseases
USD548344S1 (en) Controller for an x-ray apparatus for medical treatment
IL172397A0 (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight
USD550359S1 (en) Controller for an x-ray apparatus for medical treatment
USD545966S1 (en) Controller for an X-ray apparatus for medical treatment
IL184131A0 (en) Pyrido (3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
EP1449547A4 (en) EVACUATION TOOL FOR MEDICAL CARE
IL201447A (en) Use of 4 - cyclopropylmethoxy - n - (3, 5 - dichloro - 1 - oxydopyridine @ - @@@ - @ il @@ - 5 - (methoxy) pyridine - 2 - carboxamide for the treatment of cranial trauma
HK1111989A (en) Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
ITRM20030123A0 (it) Apparecchiatura radiogena perfezionata, in particolare per ortopantomografia delle arcate dentarie, preferibilemnte per pazienti non collabo

Legal Events

Date Code Title Description
NP Permission for amending the patent specification granted (section 66, patents law 1967)